Shares of Edinburgh-based Craneware plc fell as much as 22% on Friday after the firm published a trading update for the financial year ended June 30, 2026, saying it expects full-year performance to be below market expectations.
Craneware is a provider of healthcare financial performance software solutions for the US healthcare market.
Craneware shares fell more than 20% to around £11.54. The Edinburgh firm’s shares are now down about 40% in 2026, cutting its stock market value to roughly £395 million. In June 2025, Craneware confirmed it rejected a £26.50 per share takeover proposal from Bain Capital that would have valued the Edinburgh company at about £939.4 million.
“The Board expects the Group’s FY26 financial performance to be below market expectations, with revenue of US$205-$208 million and Adjusted EBITDA of US$65-$67 million, both broadly in line with FY25,” said the trading update.
“This change results from the timing of eligible 340B activity and the deferral of a small number of significant enterprise contracts, which are now expected to contribute during FY27. The final reported outcome remains subject to confirmation of eligible 340B activity recognised before the financial year end.
“Customer retention, customer demand and cash generation have remained strong throughout the year. Trading in the final weeks of FY26 was materially impacted by a slower than anticipated conversion of identified 340B opportunities into recognised revenue.
“Craneware continues to identify substantial opportunities for hospitals to optimise their 340B programs; with outstanding 340B qualifying drug purchases in the region of $500m, however, the pace at which those opportunities translated into eligible drug purchases slowed significantly as pharmaceutical manufacturers further expanded and operationalised restrictions on the supply of certain 340B-priced medicines.
“The Group recognises a significant proportion of this revenue upon the customer receiving the benefit from these eligible 340B drugs, rather than at the point opportunities are identified. The financial impact of this reduced conversion only became apparent once the actual amount of 340B drugs shipped to the hospitals before year end became clear.
“The Board believes that these factors reflect a short-term timing impact to the FY26 results. Looking ahead, customer demand is increasingly extending beyond software and analytics towards technology-enabled operational transformation that helps healthcare providers realise the opportunities identified by the Group’s platform.
“Craneware has been developing these capabilities over the last three years and they now represent a meaningful and growing component of the Group’s offering. This reinforces, rather than diminishes, the long-term strategic importance of Craneware’s platform within the evolving US healthcare ecosystem.
“The combination of Craneware’s trusted data, technology, AI enabled workflows and people, collectively expands the Group’s technology-enabled operational capabilities, positioning Craneware to support customers in navigating an increasingly complex healthcare environment and realise greater financial value from their operations.”
“The Board will provide a further update with the announcement of the Group’s full year results in September 2026.”
Craneware plc CEO Keith Neilson said: “Naturally we are disappointed not to have delivered the growth that we expected in FY26. While the short-term complexity in the pharmacy market has impacted the year, the long-term opportunity remains intact.
“This reinforces our strategy of expanding beyond software and analytics into technology-enabled operational transformation that helps customers realise the opportunities identified by the Group’s platform, and this is a continuing area of focus for our innovation efforts.
“We believe this strengthens both our customer relationships and our long-term growth opportunity, as healthcare providers increasingly seek trusted partners capable of combining data, workflow automation and operational expertise to deliver measurable financial outcomes. Our role is evolving from helping customers identify opportunity to helping them realise it.
“We continue to benefit from high levels of customer retention and cash generation, providing us with a strong financial foundation to execute on our strategy.”